References
- Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653-8
- Evans JR, Fletcher AE, Wormald RP. Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the Community. Br J Ophthalmol 2004;88:365-70
- Rahmani B, Tielsch JM, Katz J, et al. The cause-specific prevalence of visual impairment in an urban population. The Baltimore Eye Survey. Ophthalmology 1996;103:1721-6
- Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43
- Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995;102:1450-60
- Vingerling JR, Dielemans I, Hofman A. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995;102:205-10
- Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697-704
- Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2007;114:92-8
- Hawkins BS, Bird A, Klein R, et al. Epidemiology of age-related macular degeneration. Mol Vis 1999;5:26 . http://www.ncbi.nlm.nih.gov/pubmed/10562650
- Justiz Bd. Act on the Marketing of Drugs. Available at: http://www.gesetze-im-internet.de/amg_1976/__4.html. Section 1:4;23,3 [Last accessed 3 May 2012]
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
- Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case–control study in the Age-Related Eye Disease Study. Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000;107:2224-32
- Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-56 e744
- Ivers RQ, Cumming RG, Mitchell P, et al. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998;46:58-64
- Current opinion of the German Ophthalmological Society, and the Retina Society the Professional Association of German Ophthalmologists. The anti-VEGF therapy for neovascular age-related macular degeneration: Therapeutic Strategies, 2012. Available at: http://www.dog.org/wp-content/uploads/2009/08/Stellungnahme-Anti-VEGF-Therapie-bei-der-neovaskul%C3%A4ren-Therapeutische-Strategie-Febr-2012-final1.pdf [Last accessed 25 June 2012]
- Cho M, Athanikar A, Paccione J, et al. Optical coherence tomography features of acute central serous chorioretinopathy versus neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:597-9
- Ernst BJ, Barkmeier AJ, Akduman L. Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Int Ophthalmol 2010;30:267-70
- Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
- Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
- Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48
- Kaiser PK, Blodi BA, Shapiro H. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75
- Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-7
- Matsumiya W, Honda S, Bessho H, et al. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmol 2011;2011. Article ID: 742020 . http://www.ncbi.nlm.nih.gov/pubmed/21772985
- Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
- Evans JR. Risk factors for age-related macular degeneration. Prog Retin Eye Res 2001;20:227-53